<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332732</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-5133-103</org_study_id>
    <secondary_id>272201300019C-3-0-1</secondary_id>
    <secondary_id>17-0068</secondary_id>
    <nct_id>NCT03332732</nct_id>
  </id_info>
  <brief_title>VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers</brief_title>
  <official_title>VNRX-5133-103: A Randomized, Drug-Drug Interaction Study to Assess the Safety and Pharmacokinetics of VNRX-5133 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VenatoRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>VenatoRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part, drug-drug interaction study to evaluate potential PK interactions after
      single doses in Part 1 and multiple doses in Part 2. In Part 1, subjects will receive single
      dose of 5 treatments in a cross-over design; in Part 2 subjects will receive treatment for 10
      days.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1: Cross-over Part 2: Parallel</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of VNRX-5133 and VNRX-5022 following single doses alone and in combination (Part 1A)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of VNRX-5133 and VNRX-5022 following single doses alone and in combination (Part 1A)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>AUCinf</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of metronidazole, VNRX-5133, and VNRX-5022 (Part 1B)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of metronidazole, VNRX-5133, and VNRX-5022 (Part 1B)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Treatment Emergent Adverse Events</measure>
    <time_frame>First dose to 7 days after last dose: Part 1: 20 days / Part 2: 17 days</time_frame>
    <description>TEAEs based on patient reporting, physical exams, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation of VNRX-5133 + VNRX-5022 following multiple dose administration</measure>
    <time_frame>Part 2: 10 days</time_frame>
    <description>Trough concentration levels from Day 1 - Day 10</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bactericidal titers (Part 2)</measure>
    <time_frame>10 days</time_frame>
    <description>To evaluate serum and urine bactericidal activity at peak and trough concentrations following multiple dose administration of VNRX-5133 + VNRX-5022</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Part 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration of High Dose VNRX-5133 + VNRX-5022</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - 2C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-5133</intervention_name>
    <description>β-lactamase inhibitor</description>
    <arm_group_label>Part 1A</arm_group_label>
    <arm_group_label>Part 1B</arm_group_label>
    <arm_group_label>Part 2 - 2A</arm_group_label>
    <arm_group_label>Part 2 - 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-5022</intervention_name>
    <description>Approved β-lactam antibiotic</description>
    <arm_group_label>Part 1A</arm_group_label>
    <arm_group_label>Part 1B</arm_group_label>
    <arm_group_label>Part 2 - 2A</arm_group_label>
    <arm_group_label>Part 2 - 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Approved antibiotic and antiprotozoal medication</description>
    <arm_group_label>Part 1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (matching VNRX-5133 + VNRX-5022)</description>
    <arm_group_label>Part 2 - 2C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults

          -  Males or non-pregnant, non-lactating females

          -  Body Mass Index (BMI) between 18.5 - 32.0, inclusive

          -  Weight greater than or equal to 50 kg

          -  Suitable veins for cannulation

        Exclusion Criteria:

          -  Employee of site or the sponsor

          -  Any disease that poses an unacceptable risk to participants

          -  Abnormal ECG

          -  Abnormal labs

          -  Abnormal vital signs

          -  Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine,
             autoimmune, hematologic, neoplastic, or neurological disorder

          -  Positive serology for hepatitis B surface antigen, hepatitis C antibody, or human
             immunodeficiency virus (HIV) type 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRAHS</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

